Technology integration and access to eligible patients underpin the growth of early-phase trials in Asia Pacific
Global cooperation is needed to improve trial design and expedite new treatments specifically in low- and middle-income countries
Patient-reported outcomes in dose-finding show value in oncology trial inclusion, but shared standards are needed
Findings from studies show that patient-centred evidence can inform decisions in early-phase cancer research
Hortobagyi: “Patient involvement is central to advance research in breast cancer”
The 2025 ESMO Breast Cancer Awardee highlights that participation in clinical trials and the contribution of patient advocates is as relevant as technology to progress cancer care further
Real-world data has become integral to sarcoma research
Researchers’ confidence is growing, but the quality of the data generated may still represent a challenge
Making personalised precision medicine a reality for early breast cancer
Individualised assessment of initial response to therapy may pave the way for chemotherapy-sparing treatment, but it requires that multidisciplinary teams adapt their current practices
Treating colorectal cancer in the biomarker era – what's next?
In an interview, Prof. Julien Taieb comments on the major advances from colorectal cancer research which are driving the development of molecular-based therapies
Research in upper gastrointestinal cancers makes a leap forward
In the last few years, study findings have changed clinical practice and offered new opportunities of care to many patients
Transforming cancer care through collaborative research
Successful partnerships between industry and academia has had a positive impact on cancer drug discovery and development in prostate cancer
Advanced pancreatic cancer: is triple chemotherapy into question?
Results presented at ESMO Congress 2023 open-up an interesting debate on the use of currently recommended treatment regimens
Therapies targeting the TIGIT and STING pathways hold therapeutic promise
Safety and efficacy data of some novel immunotherapy agents are encouraging, but more research is needed to identify biomarkers and the optimal treatment schedule